David Southwell is a finance expert with a B.A. from Rice University and an M.B.A. from the Tuck School at Dartmouth College. He served as the CEO of TScan Therapeutics, Inc. from April 2018 until March 2023. Under his leadership,...

David Southwell is a finance expert with a B.A. from Rice University and an M.B.A. from the Tuck School at Dartmouth College. He served as the CEO of TScan Therapeutics, Inc. from April 2018 until March 2023. Under his leadership, the company focused on innovative therapies for cancer and other diseases. Interestingly, he stepped down without cause, which meant he received severance pay totaling $1,003,724 as part of his exit. Despite having no vested stock during 2023 due to his departure, he had a history of significant insider trading, with his wealth in TScan stock peaking at around $5.72 million in early 2021. His last compensation package for 2022 included a base salary of $622,239 with an additional performance-based cash bonus. Southwell’s exit marked a transitional phase for TScan as they welcomed new leadership, but his tenure shaped the strategic direction of the company into the realm of cutting-edge biotechnology.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other TScan Therapeutics, Inc. CEOs

T

David Southwell

Ex-CEO of TScan Therapeutics, Inc.

Education

B.A. from Rice University and an M.B.A. from the Tuck School at Dartmouth College

Field of Expertise

Finance & Banking - Finance

Sector of Economy

Healthcare

Born

January 1, 1961 - 64 years ago

CEO of TScan Therapeutics, Inc. for

1 year 11 months (Apr 2021 - Mar 2023)

Previous Experience

President, Chief Executive Officer and a member of the board of directors of Inotek Pharmaceuticals Corporation

Rivals

Competitors/colleagues of David Southwell

Holdings

See how much did David Southwell make over time.

During his time at TScan Therapeutics, David Southwell's holdings in the company's stock showed considerable growth, peaking at about $5.72 million in March 2021. However, this value fluctuated significantly, dropping below $3 million in subsequent months. By the time he...

During his time at TScan Therapeutics, David Southwell's holdings in the company's stock showed considerable growth, peaking at about $5.72 million in March 2021. However, this value fluctuated significantly, dropping below $3 million in subsequent months. By the time he stepped down, he had seen a decline in his stock value due to a lack of vested rewards and options in 2023. The peak values indicate he actively traded, reflecting an insightful approach to managing his investments in a biotech firm navigating the challenges of product development and clinical trials. This wealth in TScan stock went from less than $1.15 million in late 2019, and steadily rose as the company made strides toward innovation, hitting a high of $5.49 million shortly before his exit.

Total Stock Sold

$7.30M

RCKT

$3.38M

176,500 RCKT shares

PTCT

$3.92M

79,238 PTCT shares

What if they kept their stock?

If David Southwell didn't sell their stock, today they would have:
Extra RCKT176,500 shares worth $3.35M and PTCT79,238 shares worth $3.93M.
This is -0.27% and $19.94K less than what they got when they sold the stock.

Charitable Transactions

RCKT

172,840 shares

RCKT

PTCT

1,650 shares

PTCT

Recent Charitable Transactions

PTCT

1,650 shares

PTCT

May 8, 2024

Charity

RCKT

172,840 shares

RCKT

May 2, 2024

Charity

Insider Trading

See recent insider trades of David Southwell.

PTCT

4,000 shares

PTCT

Jan 3, 2025

Received

PTCT

1,650 shares

PTCT

May 8, 2024

Charity

RCKT

172,840 shares

RCKT

May 2, 2024

Charity

RCKT

$1.96M

RCKT at $24.48/share

Apr 12, 2024

Sale

PTCT

4,000 shares

PTCT

Feb 15, 2024

Received

PTCT

$583.58K

PTCT at $51.06/share

Apr 17, 2023

Sale

PTCT

$128.67K

PTCT at $50.05/share

Mar 31, 2023

Sale

PTCT

$453.84K

PTCT at $45.38/share

Mar 27, 2023

Sale

PTCT

4,000 shares

PTCT

Jan 5, 2023

Received

TCRX

$89.64K

TCRX at $3.59/share

May 18, 2022

Purchase

Compensation History

See how much did David Southwell make over time.

David Southwell's compensation during his time at TScan Therapeutics reflected the typical structure of an executive role in a biotech company. He earned a base salary that increased from $550,000 in 2021 to $622,239 in 2022, demonstrating solid growth in his role. In 2022, he also received a substantial performance-based cash bonus of $342,232, showcasing a focus on achieving specific corporate milestones related to product development. However, in 2023, his package notably included a severance payment totaling over $1 million due to his departure from the company. This transition also highlighted the company’s change in executive leadership, amidst ongoing growth and restructuring efforts.

Year

2023

Total Compensation

$1.16M

Salary

$153.47K

Board Justification

The compensation philosophy for the CEO aligns with company performance and retention strategies, focusing on competitive compensation to attract and retain top talent.

Bonus

$0.00

Board Justification

No bonus was awarded for the fiscal year 2023 as Mr. Southwell ceased providing services during the year.

Other

$1.00M

Board Justification

Includes severance payments totaling $1,003,724 as part of his separation agreement.

Restricted Stock

$0.00(0 N/A)

Board Justification

No stock was vested in 2023 as Mr. Southwell's options and stock awards were not exercised or vested during his tenure in 2023.

Performance Metrics

No performance metrics were applicable for the bonus as Mr. Southwell was not eligible for a bonus in 2023.

Other TScan Therapeutics, Inc. CEOs

Here are other CEOs of TScan Therapeutics, Inc.

Gavin MacBeath

CEO of TScan Therapeutics, Inc.

May 2023 - Present